Outcomes from protocol-directed active surveillance for favorable-risk prostate cancers are needed to support decision-making.
No takes yet. Share an insight, caveat, or question.
Newcomb et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: